BRC-002

Phase 2Small molecule

UUniversity of Colorado, Denver

BRC-002 is one of 44 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentNot yet recruiting

Complex Regional Pain SyndromeRecruiting

TreatmentPhase 2

Not yet recruiting

Complex Regional Pain SyndromePhase 1

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Preclinical

1 2

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 3

Lamprene

Novartis

Preclinical

1 4

Emtriva

Gilead

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

BRC-002

UUniversity of Colorado, Denver

Phase 2

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Clomid

Ferring

Preclinical

1 10

Aurlumyn

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Recruiting

Complex Regional Pain Syndrome

NCT06393101

Clinical

Trials by Indication[1]

Treatment1 trial

Tolerability and Efficacy of CBD Extract for RLS Treatment

Not yet recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07224932·60 enrolled

Complex Regional Pain Syndrome1 trial

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06393101·52 enrolled

Unspecified1 trial

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Repeat Dose and Randomized, Open-label, Crossover, Food Effect Safety, Tolerability, and Pharmacokinetic Study of BRC-002 in Healthy Participants

Enrolling by invitation·BBiopharmaceutical Research Company·Phase 1·NCT07699120·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BRC-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BRC-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BRC-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Colorado, Denver

BRC-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Treatment1 trial

Complex Regional Pain Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News